1. Home
  2. SGU vs IMRX Comparison

SGU vs IMRX Comparison

Compare SGU & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGU

Star Group L.P.

HOLD

Current Price

$12.86

Market Cap

410.0M

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.37

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGU
IMRX
Founded
1995
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.0M
340.7M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
SGU
IMRX
Price
$12.86
$5.37
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.20
AVG Volume (30 Days)
22.3K
737.9K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
5.90%
N/A
EPS Growth
N/A
37.75
EPS
N/A
N/A
Revenue
$1,784,418,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.70
N/A
Revenue Growth
1.04
N/A
52 Week Low
$11.31
$1.40
52 Week High
$13.53
$10.08

Technical Indicators

Market Signals
Indicator
SGU
IMRX
Relative Strength Index (RSI) 50.63 50.04
Support Level $12.31 $5.31
Resistance Level $12.99 $5.80
Average True Range (ATR) 0.34 0.31
MACD 0.01 -0.03
Stochastic Oscillator 39.84 28.99

Price Performance

Historical Comparison
SGU
IMRX

About SGU Star Group L.P.

Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: